Key Highlights

  • Vivani Medical shares were up 10.61 percent to USD 1.21 in pre-market trading on November 2, 2026.
  • No company announcement dated November 2, 2026 was identified as the catalyst.
  • Top-line SLIM-1 data for NPM-139 are expected in November 2026, per the company.
  • Cash, cash equivalents and restricted cash were USD 20.8 million at June 30, 2026.
  • The second quarter 2026 net loss was USD 6.4 million, versus USD 7.1 million a year earlier.

What Moved Vivani Pre-Market

Vivani Medical (NASDAQ:VANI) was up 10.61 percent to USD 1.21 in pre-market trading on November 2, 2026. The shares trade under USD 5, which makes this a Penny Stock with the usual risks of volatility, thin Liquidity and dilution.

No press release or filing dated around November 2, 2026 was identified as the cause. The rise may reflect positioning ahead of a data event the company has already flagged.

The Likely Backdrop

In its August 13, 2026 results release, the company said top-line data from the Phase 1 SLIM-1 trial of NPM-139 are expected in November 2026. All 20 participants were enrolled and dosed, as announced on August 6, 2026.

The open-label study in Australia compares ten participants on low-dose NPM-139 with ten on Wegovy 0.25 mg per week over four weeks, measuring safety, tolerability, pharmacokinetics and weight change. The company also presented at investor conferences on October 14 and 15, 2026.

Business Background and Recent Updates

Vivani is a clinical-stage biopharmaceutical company developing miniature, long-acting drug implants using its NanoPortal platform. Its lead GLP-1 programs target obesity and type 2 diabetes with dosing once or twice a year.

On July 7, 2026, the company announced a non-exclusive agreement allowing Novo Nordisk (NYSE:NVO) to evaluate NPM-139 and the NanoPortal technology. Financial terms were not disclosed, and the agreement carries no exclusivity. The company plans a Phase 2 dose-ranging trial in 2027, preceded by IND preparation.

Its Cortigent neurostimulation unit signed a definitive Merger agreement in July 2026 with ClearOne (NASDAQ:CLRO), with the combined company expected to trade as CRGT.

Balance Sheet and Risks

Cash stood at USD 20.8 million on June 30, 2026, up from USD 17.6 million at December 31, 2025 after a January 2026 private Placement and registered direct offering and share purchase tranches. Research and Development expense net of grants was USD 4.5 million for the quarter, and general and administrative expense was USD 2.4 million.

The company did not state a cash runway in the release reviewed. Clinical-stage companies with ongoing losses often raise capital, which can dilute existing holders, and a four-week study with ten participants per arm is small.

What to Watch Next

The main event is the SLIM-1 top-line readout guided for November 2026, followed by the Phase 2 plan for 2027. Updates on the Cortigent merger closing and the third quarter report are also due.

Shareholders will watch whether any filing explains the pre-market move.